MIMOSA

FOR IMMEDIATE RELEASE

International Pressure Injury Guideline Recognizes Thermographic Imaging and Tissue Oxygenation and Perfusion Monitoring as Advanced Technologies for Early Detection

Toronto, ON — August 25, 2026 — MIMOSA Diagnostics, manufacturer of the MIMOSA Pro proactive tissue intelligence imaging platform, marked a milestone for the field of non-invasive tissue assessment. The National Pressure Injury Advisory Panel (NPIAP), in collaboration with the European Pressure Ulcer Advisory Panel (EPUAP) and the Pan Pacific Pressure Injury Alliance (PPPIA), has published a new chapter, *Advanced Technologies for Skin and Tissue Assessment*, as part of the *Prevention and Treatment of Pressure Ulcers/Injuries: Clinical Practice Guideline. The International Guideline: Fourth Edition.* Published online on August 7, 2026, the chapter is the first in the guideline's history to formally address technology-assisted identification of early skin and tissue injury that occurs before it is visible to the naked eye.

The new chapter identifies four early pathophysiological changes associated with pressure injury — inflammation, sub-epidermal edema, ischemia/infarction, and tissue destruction — and names the categories of technology capable of detecting each. Devices that measure **tissue oxygenation and perfusion**, the category of technology at the core of MIMOSA Pro, are specifically identified as a means of detecting ischemia and infarction, which the guideline notes are among the early pathophysiological changes associated with the subsequent development of pressure injury.

MIMOSA Pro also utilizes thermographic imaging to provide surface temperature mapping alongside its tissue oxygenation data. This allows clinicians to detect temperature differentials—which the guideline identifies as a method to measure early inflammation and tissue destruction—giving them a powerful, multi-modal tool for comprehensive tissue assessment.

"By the time a pressure injury is visible, the damage underneath the skin has often already occurred," said **Dr. Karen Cross, MD, PhD, Co-Founder and CEO of MIMOSA Diagnostics.** "As a plastic and reconstructive surgeon, I spent years operating on the consequences of tissue damage we couldn't see coming. That's exactly the gap MIMOSA Pro was built to close, and it's why this moment matters: the international guideline that clinicians around the world rely on for pressure injury prevention has now formally recognized tissue oxygenation and perfusion assessment as part of the evidence-based path forward. This validates our technology and signals to the entire field that we can and should be detecting this tissue damage before it becomes a visible injury."

The guideline emphasizes that standard visual and tactile assessment are fundamentally limited by an inherent latency between the initial onset of pressure damage and its manifestation at the skin's surface. Because early tissue injury involves subclinical physiological changes that occur before they are visible to the naked eye, these early injuries cannot be detected on the skin's surface even under ideal conditions. This biological limitation is further compounded in clinical practice by factors such as dark skin tones, sub-optimal lighting, and varying clinician experience. Consequently, the guideline states that technologies capable of detecting these non-visible, subsurface physiological changes offer a critical way to supplement standard assessment and close the early detection gap.

MIMOSA Pro captures tissue oxygenation, surface temperature, wound measurement, and a digital image at the point of care in under one second, without requiring contact with the patient. The MIMSOA Pro is FDA-cleared and Health Canada approved (Class II) and is used by clinicians across North America to identify early signs of tissue compromise that are not yet visible to the naked eye, supporting earlier intervention in wound and pressure injury care.

"Guideline recognition is only as strong as the evidence behind it, and that's exactly why this matters," said **Anna Khimchenko, PhD, MBA, Principal, Scientific Evidence at MIMOSA Diagnostics.** "For the first time, the body of research on tissue oxygenation and perfusion as an early indicator of pressure injury has been rigorously reviewed and formally incorporated into the international standard clinicians rely on. That's a meaningful signal for where the evidence is heading, and it strengthens the case for continuing to build the clinical data that will define best practices in this space for years to come."

MIMOSA Diagnostics will continue to work alongside clinicians, researchers, and standards bodies to build the evidence base supporting multi-modal assessment technologies as a standard of care for identifying early, non-visible skin and tissue injury.

About MIMOSA Diagnostics

MIMOSA Diagnostics Inc. is a leading provider of intuitive, equitable, and accessible healthcare technology. Its flagship proactive tissue intelligence platform, the MIMOSA Pro, streamlines tissue health assessments by capturing four key insights at the point of care: wound measurements, tissue oxygenation and perfusion, thermographic imaging, and high-dynamic-range digital images. In under one second, this objective data is automatically uploaded to an accompanying secure web portal where clinicians can monitor patient progress, make timely clinical decisions, validate the efficacy of chosen treatment modalities, and collaborate towards improved patient outcomes. Learn more about MIMOSA Pro: www.mimosadiagnostics.com

Media Contact

Craig Johnson
Executive Director, Commercial Operations
craigjohnson@mimosadiagnostics.com